Actively helping customers, employees and the global community during the coronavirus SARS-CoV-2 outbreak.  Learn more >>

iFluor 750™ RGD Conjugate

Chemical structure for iFluor 750™ RGD Conjugate
Chemical structure for iFluor 750™ RGD Conjugate
Ordering information
Price ()
Catalog Number36800
Unit Size
Find Distributor
Additional ordering information
Telephone1-408-733-1055
Fax1-408-733-1304
Emailsales@aatbio.com
InternationalSee distributors
ShippingStandard overnight for United States, inquire for international
Physical properties
Molecular weight1600
SolventDMSO
Spectral properties
Correction Factor (260 nm)0.044
Correction Factor (280 nm)0.039
Correction Factor (565 nm)0.0250
Correction Factor (650 nm)0.1413
Extinction coefficient (cm -1 M -1)2750001
Excitation (nm)757
Emission (nm)779
Quantum yield0.121
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageFreeze (< -15 °C); Minimize light exposure
UNSPSC12352200

OverviewpdfSDSpdfProtocol


Molecular weight
1600
Correction Factor (260 nm)
0.044
Correction Factor (280 nm)
0.039
Correction Factor (565 nm)
0.0250
Correction Factor (650 nm)
0.1413
Extinction coefficient (cm -1 M -1)
2750001
Excitation (nm)
757
Emission (nm)
779
Quantum yield
0.121
Near-infrared fluorescence optical imaging (also called in vivo Imaging) is emerging as a powerful technology for studying diseases at molecular level in small animal models. Water and biological tissues have minimal absorbance and autofluorescence in the NIR window (650-900 nm), thus allowing efficient photon penetration into, and out of tissue with low intra-tissue scattering. Across this NIR window, light absorption by physiologically abundant molecules such as hemoglobin, oxyhemoglobin and deoxyhemoglobin is also reduced to a minimum. In vivo imaging systems with biocompatible fluorescence agents are being developed and optimized for use in the near infrared spectral region - ensuring maximum light penetration and highest sensitivity. The cell adhesion molecule integrin is involved in angiogenesis and metastasis in many tumor types. Integrin is significantly up-regulated in activated endothelial cells and fast-growing solid tumor cells, compared to its minimum expression in quiescent blood vessels and most normal tissues. iFluor® 750-labeled monomeric arginine-glycine-aspartic acid (RGD) peptide c(RGDyK) specifically targets integrin both in cell culture and in living subjects. The in vivo efficacy of iFluor® 750-c(RGDyK) depends on many factors, including the receptor affinity, specificity, molecular size, overall molecular charge, hydrophilicity and metabolic stability.

Calculators


Common stock solution preparation

Table 1. Volume of DMSO needed to reconstitute specific mass of iFluor 750™ RGD Conjugate to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.

0.1 mg0.5 mg1 mg5 mg10 mg
1 mM62.5 µL312.5 µL625 µL3.125 mL6.25 mL
5 mM12.5 µL62.5 µL125 µL625 µL1.25 mL
10 mM6.25 µL31.25 µL62.5 µL312.5 µL625 µL

Molarity calculator

Enter any two values (mass, volume, concentration) to calculate the third.

Mass (Calculate)Molecular weightVolume (Calculate)Concentration (Calculate)Moles
/=x=

Spectrum


Open in Advanced Spectrum Viewer
spectrum

Spectral properties

Correction Factor (260 nm)0.044
Correction Factor (280 nm)0.039
Correction Factor (565 nm)0.0250
Correction Factor (650 nm)0.1413
Extinction coefficient (cm -1 M -1)2750001
Excitation (nm)757
Emission (nm)779
Quantum yield0.121

Product family


NameExcitation (nm)Emission (nm)Extinction coefficient (cm -1 M -1)Quantum yieldCorrection Factor (260 nm)Correction Factor (280 nm)Correction Factor (565 nm)Correction Factor (650 nm)
iFluor® 750-streptavidin conjugate75777927500010.1210.0440.0390.02500.1413

References


View all 31 references: Citation Explorer
Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
Authors: P, undefined and ya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, Mintz A, Li KC, Wadas TJ.
Journal: Theranostics (2016): 698
c(RGDyK)-decorated Pluronic micelles for enhanced doxorubicin and paclitaxel delivery to brain glioma
Authors: Huang Y, Liu W, Gao F, Fang X, Chen Y.
Journal: Int J Nanomedicine (2016): 1629
99mTc-Glu-c(RGDyK)-Bombesin SPECT Can Reduce Unnecessary Biopsy of Masses That Are BI-RADS Category 4 on Ultrasonography
Authors: Ji T, Gao S, Liu Z, Xing H, Zhao G, Ma Q.
Journal: J Nucl Med (2016): 1196
In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide
Authors: Chen Y, Zhang W, Huang Y, Gao F, Fang X.
Journal: PLoS One (2016): e0149952
Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles
Authors: Gao Y, Zhou Y, Zhao L, Zhang C, Li Y, Li J, Li X, Liu Y.
Journal: Acta Biomater (2015): 127
Dual-functional c(RGDyK)-decorated Pluronic micelles designed for antiangiogenesis and the treatment of drug-resistant tumor
Authors: Chen Y, Zhang W, Huang Y, Gao F, Fang X.
Journal: Int J Nanomedicine (2015): 4863
The C(RgdyK)-conjugated Fe3O4 nanoparticles with high drug load for dual-targeting integrin alpha(v)beta3-expressing cancer cells
Authors: Guo L, Ding W, Zheng LM.
Journal: J Nanosci Nanotechnol (2014): 4858
Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors
Authors: Oxboel J, Br and t-Larsen M, Schjoeth-Eskesen C, Myschetzky R, El-Ali HH, Madsen J, Kjaer A.
Journal: Nucl Med Biol (2014): 259
Synthesis and characterization of theranostic poly(HPMA)-c(RGDyK)-DOTA-64Cu copolymer targeting tumor angiogenesis: tumor localization visualized by positron emission tomography
Authors: Yuan J, Zhang H, Kaur H, Oupicky D, Peng F.
Journal: Mol Imaging (2013): 203
Design and biological evaluation of (9)(9)mTc-N(2)S(2)-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing alpha(v)beta(3) integrins
Authors: Ocampo-Garcia BE, Santos-Cuevas CL, De Leon-Rodriguez LM, Garcia-Becerra R, Ordaz-Rosado D, Luna-Guitierrez MA, Jimenez-Mancilla NP, Romero-Pina ME, Ferro-Flores G.
Journal: Nucl Med Biol (2013): 481